Inertial waves and modes excited by the libration of a rotating cube

We report experimental measurements of the flow in a cubic container submitted to a longitudinal libration, i.e. a rotation modulated in time. Velocity fields in a vertical and a horizontal plane are measured in the librating frame using a corotating particle image velocimetry system. When the libration frequency $\sigma_0$ is smaller than twice the mean rotation rate $\Omega_0$, inertial waves can propagate in the interior of the fluid. At arbitrary excitation frequencies $\sigma_0<2\Omega_0$, the oscillating flow shows two contributions: (i) a basic flow induced by the libration motion, and (ii) inertial wave beams propagating obliquely upward and downward from the horizontal edges of the cube. In addition to these two contributions, inertial modes may also be excited at some specific resonant frequencies. We characterize in particular the resonance of the mode of lowest order compatible with the symmetries of the forcing, noted [2,1,+]. By comparing the measured flow fields to the expected inviscid inertial modes computed numerically [L.R.M. Maas, Fluid Dyn. Res. \textbf{33}, 373 (2003)], we show that only a subset of inertial modes, matching the symmetries of the forcing, can be excited by the libration.Comment: Phys. Fluids (in press

Assessing a treatment on the basis of an individual or a group. An example: the homeopathic treatment of digestive-tract strongyles in sheep

Homeopathic treatments, widely used in organic farming, remain unevaluated. Assessment is difficult since the individuals that respond to treatment are not identified, although it is central to the concept of homeopathic treatment. Classifying lambs into those to be treated (since they have high parasitic infection rate or poor production performances) or that should remain untreated (in other words, even when treated, they will not benefit from treatment) is not simple. The identification of lambs to be treated can be based on parasitological examinations (eggs per gram of faeces), clinical (anaemia or diarrhoea)or production-related (weight gain) results. The classification of lambs was a posteriori and based on dendrograms using UPGMA (unweighted pairwise grouping on arithmetic average) and Gower’s similarity index. Parasitological, clinical and production identifiers were used for assessing the efficacy of Teucrium marum (9 CH) on digestive-tract strongyles. There was no reduction in gastro-intestinal infection in lambs with high infection rates or poor live weight gain

Functional and Taxonomic Diversity of Collembola as Complementary Tools to Assess Land Use Effects on Soils Biodiversity

Collembola have been proposed for several decades as a good model organisms to survey soil biodiversity; but most of the studies focused on taxonomic endpoints. The main objectives of this study are to compare the effects of the different land uses, including urban and industrial land uses, while using both collembolan functional and taxonomic biodiversity approaches. We collected data on 3,056 samples of Collembola communities across 758 sites in various land uses throughout France. The types of land use considered included all types of human activity from forestry to urban, industrial, traffic, mining and military areas, agricultural grassland, arable land, vineyards and urban vegetable gardens. In order to study functional and taxonomic biodiversity, we used community-weighted means, functional indices, species richness and density. When looking at collembolan functional diversity, urban and industrial soils appear clearly less diversified than when considering the taxonomic diversity. We suspect here a functional homogenization effect commonly reported in the literature for various organisms in urban ecosystems. Our study provides range of values for different taxonomic and functional indices of Collembola communities in a wide land use classification across France

Expert opinion on pituitary complications in immunotherapy

Hypophysitis is a frequent toxic endocrine side-effect of immunotherapy. Prevalence is higher with anti-CTLA-4 antibodies (4-20%) or in association with PD-1 inhibitors (8%). Diagnosis is presumptive, based on poorly specific clinical symptoms (usually, headache and asthenia) and/or hyponatremia and/or at least one pituitary deficit and/or abnormal imaging. Visual disorder or polyuropolydipsic syndrome are exceptional. In decreasing order of frequency, deficits are thyrotropic (86-100%), gonadotropic (85-100%) or corticotropic (50-73%); somatotropin deficit or abnormal prolactin level are rarer. Pituitary MRI in acute phase shows variable moderate increase in pituitary volume, ruling out differential diagnoses, especially pituitary metastasis. Treatment of corticotropin deficiency requires systematic emergency replacement therapy, with the usual modalities, while treatment of other deficits depends on clinical status and progression. Thyrotropin and gonadotropin deficits usually recover, but corticotropin deficiency persists over the long term, requiring education and specialized endocrinologic follow-up. Onset of hypophysitis does not contraindicate continuation of immunotherapy and does not usually require high dose synthetic glucocorticoids

Identification of hip fracture patients from radiographs using Fourier analysis of the trabecular structure: a cross-sectional study

Peer reviewedPublisher PD

Male osteoporosis: diagnosis and fracture risk evaluation

Male osteoporosis is challenging to diagnose and to treat. Underestimation of the risk of male osteoporosis, the combined presence of several interwoven causative factors in many patients, and uncertainty regarding the absorptiometry cutoffs associated with fractures are major obstacles to the diagnosis of male osteoporosis and to the identification of men at risk for fractures. The lifetime risk of osteoporotic fracture is estimated at 15% among men older than 50 years. One-third of proximal femoral fractures occur in men, and the associated mortality rate is 2- to 3-fold that in women. In men, nearly half the cases of osteoporosis are related to disease, medications, or risk factors. Although the criteria for diagnosing male osteoporosis are not agreed on, the definitions developed by the World Health Organization can be used provided the reference population is composed of young males. An absorptiometry T-score &lt; or = -2.5 is useful for diagnosing osteoporosis but fails to adequately predict the fracture risk. The identification of men at high risk for fractures requires a combined evaluation of bone mineral density data, clinical risk factors, and risk factors for falls

2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis

OBJECTIVES: To update the evidence-based position statement published by the French National Authority for Health (HAS) in 2006 regarding the pharmacological treatment of postmenopausal osteoporosis, under the auspices of the French Society for Rheumatology and Groupe de Recherche et d\u27Information sur les Ostéoporoses (GRIO), and with the participation of several learned societies (Collège National des Gynécologues et Obstétriciens Français, Groupe d\u27Étude de la Ménopause et du Vieillissement hormonal, Société Française de Chirurgie Orthopédique, Société Française d\u27Endocrinologie, and Société Française de Gériatrie et de Gérontologie). METHODS: A multidisciplinary panel representing the spectrum of clinical specialties involved in managing patients with postmenopausal osteoporosis developed updated recommendations based on a systematic literature review conducted according to the method advocated by the HAS. RESULTS: The updated recommendations underline the need for osteoporosis pharmacotherapy in women with a history of severe osteoporotic fracture. In these patients, any osteoporosis medication can be used; however, zoledronic acid is the preferred first-line medication after a hip fracture. In patients with non-severe fractures or no fractures, the appropriateness of osteoporosis pharmacotherapy depends on the bone mineral density and FRAX(®) values; any osteoporosis medication can be used, but raloxifene and ibandronate should be reserved for patients at low risk for peripheral fractures. Initially, osteoporosis pharmacotherapy should be prescribed for 5 years. The results of the evaluation done at the end of the 5-year period determine whether further treatment is in order. CONCLUSIONS: These updated recommendations are intended to provide clinicians with clarifications about the pharmacological treatment of osteoporosis

Severe osteoporosis: diagnosis and follow-up. Lessons for clinical practice

The management of osteoporosis has improved considerably, leading to the development of new goals. A major concern today is the management of patients with severe osteoporosis, in whom the need for pharmacotherapy is clear [1]. Epidemiological data have established that osteoporosis is associated with severe complications [2,3]. Furthermore, osteoporosis is now recognized as a complication of several chronic diseases, whose presence adversely affects the management of osteoporosis. The ODISSEE task force (Osteoporosis DIagnosis and Surveillance of SEvErity) was established to answer practical questions regarding the management of severe osteoporosis, based on evidence in the literature. Several groups conducted an exhaustive literature review, and advice was obtained from a panel of French rheumatologists. The ODISSEE scientific committee then developed the first consensus statement on the diagnosis, follow-up and management of severe osteoporosis. This statement was validated by a panel of 70 French rheumatologists at the first national ODISSEE meeting held on November 13-14, 2009

Management of male osteoporosis: lessons for clinical practice

International audienc